Predictive Factors of Successful Double J Stent Insertion Among Advanced Cervical Cancer Patients.

IF 2.1 Q3 ONCOLOGY World Journal of Oncology Pub Date : 2024-04-01 Epub Date: 2024-03-21 DOI:10.14740/wjon1631

Syah Mirsya Warli, Mohd Rhiza Z Tala, William Saputra Wijaya

{"title":"Predictive Factors of Successful Double J Stent Insertion Among Advanced Cervical Cancer Patients.","authors":"Syah Mirsya Warli, Mohd Rhiza Z Tala, William Saputra Wijaya","doi":"10.14740/wjon1631","DOIUrl":null,"url":null,"abstract":"Background: Cervical cancer remains the most lethal and prevalent cancer among women. Obstructive uropathy is a common complication of advanced cervical cancer, caused by the expanding tumor. One of the recommended treatments for this condition is the implantation of a double J (DJ) stent. However, this procedure is challenging due to the unique characteristics of the patient. The objective of this study was to identify the variables that influence the successful insertion of a DJ stent in women with advanced cervical cancer.Methods: This retrospective study included women who attempted to have a DJ stent implanted at the General Hospital of Adam Malik in Medan, Indonesia, between January 2020 and December 2022, and were diagnosed with advanced cervical cancer. The inclusion criteria were limited to cervical cancer patients in stages III-IV, according to the International Federation of Gynecology and Obstetrics (FIGO) staging standard, who underwent an attempt at DJ stent insertion. Patients who underwent a nephrostomy and received a DJ stent were excluded from the study. The participants were divided into two groups based on the success of the DJ stent implantation. The analysis was conducted using the logistic regression test and the Chi-square test.Results: The study included 88 patients with advanced-stage cervical cancer, of whom 45 underwent nephrostomy and 43 received a DJ stent. The analysis revealed that lower levels of hydronephrosis (odds ratio (OR): 18.203, P = 0.001), urea (OR: 4.207, P = 0.037), and creatinine (OR: 6.923, P = 0.004), higher levels of urine output (OR: 8.26, P = 0.003), and lower cervical cancer stage (OR: 4.125, P = 0.022) were all predictors of successful DJ stent insertion.Conclusion: For women with advanced cervical cancer, lower degrees of hydronephrosis, urea, and creatinine levels, higher urine output, and lower cervical cancer stage were all predictive factors for successful DJ stent implantation.","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"15 2","pages":"239-245"},"PeriodicalIF":2.1000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965259/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/wjon1631","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cervical cancer remains the most lethal and prevalent cancer among women. Obstructive uropathy is a common complication of advanced cervical cancer, caused by the expanding tumor. One of the recommended treatments for this condition is the implantation of a double J (DJ) stent. However, this procedure is challenging due to the unique characteristics of the patient. The objective of this study was to identify the variables that influence the successful insertion of a DJ stent in women with advanced cervical cancer.

Methods: This retrospective study included women who attempted to have a DJ stent implanted at the General Hospital of Adam Malik in Medan, Indonesia, between January 2020 and December 2022, and were diagnosed with advanced cervical cancer. The inclusion criteria were limited to cervical cancer patients in stages III-IV, according to the International Federation of Gynecology and Obstetrics (FIGO) staging standard, who underwent an attempt at DJ stent insertion. Patients who underwent a nephrostomy and received a DJ stent were excluded from the study. The participants were divided into two groups based on the success of the DJ stent implantation. The analysis was conducted using the logistic regression test and the Chi-square test.

Results: The study included 88 patients with advanced-stage cervical cancer, of whom 45 underwent nephrostomy and 43 received a DJ stent. The analysis revealed that lower levels of hydronephrosis (odds ratio (OR): 18.203, P = 0.001), urea (OR: 4.207, P = 0.037), and creatinine (OR: 6.923, P = 0.004), higher levels of urine output (OR: 8.26, P = 0.003), and lower cervical cancer stage (OR: 4.125, P = 0.022) were all predictors of successful DJ stent insertion.

Conclusion: For women with advanced cervical cancer, lower degrees of hydronephrosis, urea, and creatinine levels, higher urine output, and lower cervical cancer stage were all predictive factors for successful DJ stent implantation.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

晚期宫颈癌患者成功植入双 J 支架的预测因素

背景：宫颈癌仍然是妇女中致死率最高、发病率最高的癌症。梗阻性尿路病变是晚期宫颈癌的常见并发症，是由肿瘤不断扩大引起的。推荐的治疗方法之一是植入双 J（DJ）支架。然而，由于患者的特殊性，这一手术具有挑战性。本研究旨在确定影响晚期宫颈癌女性成功植入 DJ 支架的变量：这项回顾性研究纳入了 2020 年 1 月至 2022 年 12 月期间在印度尼西亚棉兰市亚当-马利克总医院尝试植入 DJ 支架并被确诊为晚期宫颈癌的女性患者。纳入标准仅限于根据国际妇产科联盟（FIGO）分期标准分期为III-IV期并尝试植入DJ支架的宫颈癌患者。接受了肾造瘘术并接受了DJ支架的患者不在研究范围内。根据 DJ 支架植入的成功率将参与者分为两组。采用逻辑回归检验和卡方检验进行分析：研究包括 88 名晚期宫颈癌患者，其中 45 人接受了肾造瘘术，43 人接受了 DJ 支架植入术。分析显示，较低的肾积水水平（几率比（OR）：18.203，P = 0.001）、尿素水平（OR：4.207，P = 0.037）和肌酐水平（OR：6.923，P = 0.004）、较高的尿量水平（OR：8.26，P = 0.003）以及较低的宫颈癌分期（OR：4.125，P = 0.022）都是成功插入 DJ 支架的预测因素：结论：对于患有晚期宫颈癌的妇女来说，较低的肾积水程度、尿素和肌酐水平、较高的尿量和较低的宫颈癌分期都是成功植入 DJ 支架的预测因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

World Journal of Oncology ONCOLOGY-

CiteScore

6.10

自引率

15.40%

发文量

期刊介绍： World Journal of Oncology, bimonthly, publishes original contributions describing basic research and clinical investigation of cancer, on the cellular, molecular, prevention, diagnosis, therapy and prognosis aspects. The submissions can be basic research or clinical investigation oriented. This journal welcomes those submissions focused on the clinical trials of new treatment modalities for cancer, and those submissions focused on molecular or cellular research of the oncology pathogenesis. Case reports submitted for consideration of publication should explore either a novel genomic event/description or a new safety signal from an oncolytic agent. The areas of interested manuscripts are these disciplines: tumor immunology and immunotherapy; cancer molecular pharmacology and chemotherapy; drug sensitivity and resistance; cancer epidemiology; clinical trials; cancer pathology; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; gene therapy; cancer endocrinology; cancer metastasis; prevention and diagnosis of cancer; other cancer related subjects. The types of manuscripts accepted are original article, review, editorial, short communication, case report, letter to the editor, book review.